cGAS-STING信号通路是大多数癌症治疗的重要组成部分。近年来对肿瘤免疫调节网络的累积了解促进了cGAS-STING激动剂作为一种有效的免疫治疗策略用于肿瘤治疗的发展。然而，由于低免疫刺激效果和临床相关条件下的副作用无法控制，这些激动剂的临床转化目前仍然不理想。有趣的是，合理地整合生物材料技术为更有效和更安全的cGAS-STING介导的肿瘤治疗提供了有希望的方法。在这篇文章中，我们首先概述了cGAS-STING信号通路并讨论其与肿瘤的关系。然后，我们对那些基于生物材料的cGAS-STING激动剂策略的最近进展进行了对称总结，以化学性质和载体基质的分类方式产生强大的抗肿瘤免疫反应。最后，提供了一个展望，以讨论cGAS-STING调节在肿瘤治疗中存在的挑战和潜在机会。版权所有©2023年美国基因和细胞治疗学会。由Elsevier Inc.出版。保留所有权利。

cGAS-STING signaling is a central component in the therapeutic action of most existing cancer therapies. The accumulated knowledge of tumor immunoregulatory network in recent years has spurred the development of cGAS-STING agonists for tumor treatment as an effective immunotherapeutic strategy. However, the clinical translation of these agonists is thus far unsatisfactory due to low immunostimulatory efficacy and unrestricted side effects under clinically relevant conditions. Interestingly, the rational integration of biomaterial technology offers a promising approach to overcome these limitations for more effective and safer cGAS-STING-mediated tumor therapy. Herein, we first outline the cGAS-STING signaling axis and generally discuss its association with tumors. We then symmetrically summarize the recent progress in those biomaterial-based cGAS-STING agonism strategies to generate robust antitumor immunity, categorized by the chemical nature of those cGAS-STING stimulants and carrier substrates. Finally, a perspective is provided to discuss the existing challenges and potential opportunities in cGAS-STING modulation for tumor therapy.Copyright © 2023 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.